Novo Nordisk A/S posted hefty gains in sales and operating profit for the third quarter and first nine months of 2014 driven by demand for the long-acting insulin product Levemir and the glucagon-like peptide-1 agonist (GLP-1) Victoza. ---Subscribe to MedNous to access this article--- Company News
